Algenex y Neurofix: dos casos de éxito

from Biotecnología Capital · host Capital Radio

En el marco de BioSpain 21 tuvimos la oportunidad de hablar con dos empresas muy interesantes. La primera es Algenex y hablamos con su fundador y director científico, José Escribano. En segundo lugar charlamos con el CEO, Mario Grande, y el director general Miguel Ángel Ávila, de Neurofix.

Episode metadata supplied by the publisher feed · Published Aug 11, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Algenex y Neurofix: dos casos de éxito

0:00 29:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Biotecnología Capital?

This episode is 29 minutes long.

When was this Biotecnología Capital episode published?

This episode was published on August 11, 2021.

Can I download this Biotecnología Capital episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!